Vitamin D levels in IBD: a randomised trial of weight-based
versus fixed dose vitamin D supplementation

J 2020

Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation

KOJECKÝ, Vladimír; Jan MATOUS; Bohuslav KIANIČKA; Petr DITE; Zdena ZADOROVA et. al.

Základní údaje

Originální název

Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation

Autoři

KOJECKÝ, Vladimír (203 Česká republika, domácí); Jan MATOUS (203 Česká republika); Bohuslav KIANIČKA (203 Česká republika, garant); Petr DITE (203 Česká republika); Zdena ZADOROVA (203 Česká republika); Jan KUBOVY (203 Česká republika); Martina HLOSTOVA (203 Česká republika) a Michal UHER (203 Česká republika, domácí)

Vydání

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, ABINGDON, TAYLOR & FRANCIS LTD, 2020, 0036-5521

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.425

Kód RIV

RIV/00216224:14110/20:00116133

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1080/00365521.2020.1774921

UT WoS

000545392100001

EID Scopus

2-s2.0-85086906005

Klíčová slova anglicky

Inflammatory bowel disease; vitamin D deficiency; vitamin D intake; dietary supplements; body weight

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 8. 2020 10:43, Mgr. Tereza Miškechová

Anotace

V originále

Objectives:Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD). Materials/methods:This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period. Results:A total of 173 patients were analysed. The mean BMI was 25.5 +/- 5.1 and initial mean 25OHD level was 62.7 +/- 25.5 nmol/l. A similar increase (9.7 +/- 26.9 vs 9.8 +/- 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p < .001) and negatively with the baseline 25OHD level (p < .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU. Conclusions:Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.

Citovat

KOJECKÝ, Vladimír; Jan MATOUS; Bohuslav KIANIČKA; Petr DITE; Zdena ZADOROVA; Jan KUBOVY; Martina HLOSTOVA a Michal UHER. Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. ABINGDON: TAYLOR & FRANCIS LTD, 2020, roč. 55, č. 6, s. 671-676. ISSN 0036-5521. Dostupné z: https://dx.doi.org/10.1080/00365521.2020.1774921.

@article{1673167,
   author = {Kojecký, Vladimír and Matous, Jan and Kianička, Bohuslav and Dite, Petr and Zadorova, Zdena and Kubovy, Jan and Hlostova, Martina and Uher, Michal},
   article_location = {ABINGDON},
   article_number = {6},
   doi = {http://dx.doi.org/10.1080/00365521.2020.1774921},
   keywords = {Inflammatory bowel disease; vitamin D deficiency; vitamin D intake; dietary supplements; body weight},
   language = {eng},
   issn = {0036-5521},
   journal = {SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY},
   title = {Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation},
   url = {https://www.tandfonline.com/doi/full/10.1080/00365521.2020.1774921},
   volume = {55},
   year = {2020}
}

TY  - JOUR
ID  - 1673167
AU  - Kojecký, Vladimír - Matous, Jan - Kianička, Bohuslav - Dite, Petr - Zadorova, Zdena - Kubovy, Jan - Hlostova, Martina - Uher, Michal
PY  - 2020
TI  - Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation
JF  - SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
VL  - 55
IS  - 6
SP  - 671-676
EP  - 671-676
PB  - TAYLOR & FRANCIS LTD
SN  - 00365521
KW  - Inflammatory bowel disease
KW  - vitamin D deficiency
KW  - vitamin D intake
KW  - dietary supplements
KW  - body weight
UR  - https://www.tandfonline.com/doi/full/10.1080/00365521.2020.1774921
L2  - https://www.tandfonline.com/doi/full/10.1080/00365521.2020.1774921
N2  - Objectives:Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD). Materials/methods:This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period. Results:A total of 173 patients were analysed. The mean BMI was 25.5 +/- 5.1 and initial mean 25OHD level was 62.7 +/- 25.5 nmol/l. A similar increase (9.7 +/- 26.9 vs 9.8 +/- 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p < .001) and negatively with the baseline 25OHD level (p < .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU. Conclusions:Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.
ER  -

KOJECKÝ, Vladimír; Jan MATOUS; Bohuslav KIANIČKA; Petr DITE; Zdena ZADOROVA; Jan KUBOVY; Martina HLOSTOVA a Michal UHER. Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation. \textit{SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2020, roč.~55, č.~6, s.~671-676. ISSN~0036-5521. Dostupné z: https://dx.doi.org/10.1080/00365521.2020.1774921.

Přehled o publikaci